Friday, May 29, 2009 12:02:30 PM
CTIC ...
!
Full 2009 ASCO Cancer & Oncology Primer
Cell Therapeutics (NASDAQ: CTIC) is set to present its Pixantrone Phase III study results in June 1. At $1.23 its market cap is still listed around $560 million. That may have changed due to a tender, but its 52-week range is listed as $0.05 to $6.50. “Volatility is our middle name!”
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=38222764
! Full 2009 ASCO Cancer & Oncology Primer
Cell Therapeutics (NASDAQ: CTIC) is set to present its Pixantrone Phase III study results in June 1. At $1.23 its market cap is still listed around $560 million. That may have changed due to a tender, but its 52-week range is listed as $0.05 to $6.50. “Volatility is our middle name!”
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=38222764
posts are IMHO // either news - with LINK
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
